Glycopyrroniumbromid

GLYCOPYRRONIUM · GLYCOPYROLATE · Glycopyrronium impurity N · robinul · Glycopyrrone bromide · Glycopyrronium for peak identification · Glycopyrronium for peak identification CRS · Pyrrolidinium, 3-(cyclopentylhydroxyphenylacetyl)oxy-1,1-dimethyl-, bromide

https://huagongshe.com/de/chemical/11693

Molekülstruktur von Glycopyrroniumbromid

Identifikatoren & physikalische Daten

CAS No.	596-51-0
Summenformel	C19H28BrNO3
Durchschnittliche Molmasse	398,3 g/mol
SMILES	C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]
InChIKey	VPNYRYCIDCJBOM-UHFFFAOYSA-M
PubChem CID	11693
ChEMBL	CHEMBL1201027
ChEBI	CHEBI:90972
EC No.	209-887-0
DTXSID	DTXSID6023109
Lokaler Name	Glycopyrroniumbromid

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)	46,5
H-Brücken-Donoren	1
H-Brücken-Akzeptoren	4
Frei drehbare Bindungen	5
Schwere Atome	24
Formalladung	0
Komplexität	424
Human Drugs	Breast FeedingLactationMilk, HumanAdjuvants, AnesthesiaBronchodilator AgentsMuscarinic AntagonistsParasympatholyticsFDA approved drugs -> Active ingredientEMA approved medicines: Human medicine
Animal Drugs	Active Ingredients (Glycopyrrolate) -> FDA Greenbook
Collision Cross Section	203.8 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
Schmelzpunkt	192-195°C
Dichte	1.3222 (rough estimate)
Brechungsindex	1.6200 (estimate)
Lagerbedingungen	2-8°C
Löslichkeit	H2O: ≥24mg/mL
Aggregatzustand	powder
Farbe	white to tan
Merck	14,4501
Stabilität	Hygroscopic
InChI	InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H31H/q+1/p-1
InChIKey	VPNYRYCIDCJBOM-UHFFFAOYSA-M
SMILES	C(O)(C(=O)OC1CC[N+](C)(C)C1)(C1=CC=CC=C1)C1CCCC1.[Br-]
CAS Datenbank	596-51-0(CAS DataBase Reference)

Sicherheit & Vorschriften

GHS-Einstufung	WarningH302 (23.5%): Harmful if swallowed [Warning Acute toxicity, oral]P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 51 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Regulatorische Informationen	Glycopyrronium bromide: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Weitere Sicherheitsinformationen	IMAP assessments - Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide: Environment tier I assessment
Hazard Classes and Categories	Acute Tox. 4 (23.5%)
Hepatotoxicity	Like other anticholinergic agents, glycopyrrolate has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury. A major reason for its safety may relate to the low daily dose.
Unerwünschte Wirkungen	Potential adverse reactions associated with glycopyrrolate administration include anticholinergic symptoms such as mydriasis, hyperthermia, tachycardia, and cardiac arrhythmia. They may also include blurred vision, constipation, cycloplegia, dry mouth, dry skin, flushing, photophobia, urinary retention, and xerophthalmia.
Toxizitätsübersicht	Acute toxicity with glycopyrrolate is secondary to an extension of the pharmacologic effects on the muscarinic cholinergic receptors. Muscarinic receptor sites are located in the brain's cerebral cortex, thalamus, hippocampus, and reticular activating system. They are also present in the postganglionic parasympathetic nervous system and other sites like sweat glands. Anticholinergic agents block the effects of acetylcholine by competitively binding and blocking muscarinic receptors.
Drug Induced Liver Injury	Drug Induced Liver Injury Rank (DILIrank 2.0)GlycopyrrolatevNo-DILI-concern

Anwendungen & Verwendung

Beschreibung

Glycopyrrolate is an antagonist of muscarinic acetylcholine receptors (mAChRs; Kis = 0.42, 1.77, 0.52, 0.78, and 1.29 nM for the M1-M5 receptors, respectively). It induces relaxation of precontracted isolated human bronchi when used at concentrations of 0.01, 0.1, or 1 μM. Glycopyrrolate reduces post-prandial gastric antral motility in dogs when administered at a dose of 0.01 mg/kg. It inhibits salivation in a rat model of sialorrhea induced by pilocarpine with an ED50 value of 0.74 μg/kg. Formulations containing glycopyrrolate have been used in the treatment of sialorrhea, peptic ulcers, and chronic obstructive pulmonary disease (COPD).

Verwenden

Glycopyrrolate inhibits secretion of digestive juices and restores normal stomach function. It is used for treating stomach ulcers, inflamed intestine, and also as a pre-operational drug for inhibiting excess stomach secretion.

Verwenden

A synthetic, quaternary ammonium anticholinergic. Antispasmodic; preanesthetic medicant.